8-K: Virpax Pharmaceuticals Reports 2023 Year-End Results and Provides Business Update

Virpax Pharmaceuticals announced its 2023 year-end financial results, highlighting progress in clinical trials, regulatory submissions, and strategic partnerships.

Summary

• Virpax Pharmaceuticals reported a net loss of $15.2 million for the year ended December 31, 2023, compared to a $21.7 million loss in 2022.
• Operating expenses decreased to $15.7 million in 2023 from $21.8 million in 2022, primarily due to lower legal defense costs and reduced research and development spending on certain programs.
• The company's cash balance was approximately $9.1 million as of December 31, 2023, down from $19.0 million at the end of 2022.
• Virpax is advancing its pipeline, including Probudur, Envelta, and NobrXiol, with plans to file Investigational New Drug (IND) applications for Probudur and Envelta in 2024.
• The company has regained compliance with Nasdaq's minimum bid price requirement and settled litigation with Sorrento Therapeutics and Scilex Pharmaceuticals.
• Virpax is actively pursuing non-dilutive funding through government grants and exploring sublicensing opportunities for its pain assets.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments, such as reduced losses and regained Nasdaq compliance, alongside negative aspects like a significant decrease in cash. The overall tone is cautiously optimistic, with a focus on future milestones.

Positives

• The company has reduced its operating loss and research and development expenses year-over-year.
• Virpax has successfully regained compliance with Nasdaq listing requirements.
• The settlement of litigation removes a significant legal hurdle.
• Positive initial results from the Probudur pilot study support further development.
• The company is actively pursuing non-dilutive funding through government grants.
• Virpax is making progress with its lead pain assets in both the global animal healthcare market and assessing potential geographical opportunities.

Negatives

• The company's cash balance decreased significantly from $19.0 million to $9.1 million year-over-year.
• The company reported a net loss of $15.2 million for the year.
• The company has a significant accumulated deficit of $59.5 million.

Risks

• The company's ability to obtain additional capital to meet its short and long-term liquidity needs is a risk.
• There are risks associated with completing research and development, clinical trials, and obtaining regulatory approvals.
• Competition and changes in the regulatory landscape could impact the company's product candidates.
• The loss of key personnel could negatively affect the company.
• The company's ability to protect its intellectual property is a risk.

Future Outlook

Virpax plans to file IND applications for Probudur and Envelta in 2024, initiate a head-to-head study of Probudur, and continue to pursue government grants and sublicensing opportunities. The company expects to achieve significant milestones this year.

Management Comments

• We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq, commented Gerald W. Bruce, Chief Executive Officer of Virpax.
• We have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management, commented Gerald W. Bruce, Chief Executive Officer of Virpax.
• The findings were in line with our expectations and support our earlier studies of Probudur, continued Mr. Bruce.
• We are excited for the USAISRs next study which as planned would be a head-to-head comparison with free bupivacaine and EXPAREL and expect it to start mid-year, continued Mr. Bruce.
• As of today, we are still on track to file the IND later in 2024, added Mr. Bruce.
• We are continuing to develop Envelta, our non-addictive pain product candidate for acute and chronic pain, with the NIH under our NCATS in-kind grant and are making progress towards filing the IND, added Mr. Bruce.
• Our team is committed to the important and potentially game-changing product candidates that are under development, and their efforts are greatly appreciated, concluded Mr. Bruce.

Industry Context

The announcement comes amid a challenging period for the biotech industry, with Virpax highlighting its focus on non-addictive pain management solutions, a growing area of interest due to the opioid crisis. The company's partnerships with government agencies like the NIH and DOD are also notable in the context of industry trends towards public-private collaborations.

Comparison to Industry Standards

• Virpax's decrease in operating expenses and R&D spending is a positive sign, especially when compared to other biotech companies that often struggle with high burn rates.
• The company's focus on non-dilutive funding through government grants is a strategic move that aligns with best practices in the biotech sector, where securing external funding is crucial.
• The progress of Probudur and Envelta is comparable to other companies developing novel pain management therapies, with the head-to-head study of Probudur being a key milestone.
• The company's cash position of $9.1 million is relatively low compared to other companies at a similar stage of development, highlighting the need for additional funding.

Management Changes

Legal Proceedings

• The litigation settlement and mutual release agreement between the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. was approved by the United States Bankruptcy Court for the Southern District of Texas.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split and the company's financial performance.
• Employees may be affected by the company's cost-cutting measures and strategic shifts.
• Customers and patients may benefit from the development of new pain management products.
• Suppliers and partners will be impacted by the company's ongoing research and development activities.
• Creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to file an IND for Probudur later in 2024.
• The company plans to initiate a head-to-head study of Probudur against free bupivacaine and EXPAREL mid-year.
• The company plans to file an IND for Envelta in mid-2024 and initiate first in human trials in 2024.
• The company will continue to pursue government grants and sublicensing opportunities.

Key Dates

Keywords

Virpax Pharmaceuticals, pain management, Probudur, Envelta, clinical trials, IND, government grants, non-addictive, biotechnology, pharmaceuticals